Vir is developing treatments in billion-dollar markets.
News & Analysis: Vir Biotechnology Inc
One of the three clearly has the most upside potential.
Which stock has more potential for growth over the next year? Let's look to the stars for an answer.
Investors are excited about the potential of the company's investigational coronavirus therapy.
The relationship could result in a marriage down the line.
The biotech's pipeline gets a seal of approval.
Bearish commentary from an analyst may be to blame.
The company provided a discouraging regulatory update.
The biotech will get $345 million through an upfront payment and equity investment.
The biotech is expanding its collaboration with a big partner.